Immunogenetic and immunologic markers of early rheumatoid arthritis. RADIKAL program first stage results

Objective. To assess frequency of immunogenetic (HLA-DRB I allels) and immunologic - anti-cyclic citrullinated peptide antibodies (ACCP), IgM rheumatoid factor (RF) - parameters and their significance as markers of early rheumatoid arthritis (RA). Material and methods. HLA-DRB 1 alleles, ACCP and IgM RF were evaluated in 95 pts with early RA who fulfilled ACR criteria 1987 with disease duration 2 years or less. In 85,3% of them disease duration was <12 months. 135 blood donors without autoimmune diseases and relevant compromised inheritance. Basic low-resolving oligo-typing of HLA- DRB 1 gene and high-resolving oligo-typing of HLA-DRB 1*04 alleles was performed with multiplex polymerase chain reaction. ACCP2 and IgM RF levels were evaluated by immunoenzyme assay and nephelometric immunoassay with commercial kits. Results. Early RA group showed higher frequency of HLA-DRB 1 allele than control group (45,3% and 15,6% respectively, OR=4,5, 95% Cl 2,3-8,7). *05, *06 and *07 alleles in RA group were significantly less frequent than in control. *0401 allele was most frequent (25,3%) among HLA-DRB 1*04. Double dose SE+/SE+ (double set of any from *01,*0401, *0404, *0405, *0408, *10) was revealed in 33,7% of RA group pts and in 5,2% of cases in control group (OR=9,3, 95% Cl 3,7-24,6, p=lxl0 7). Absence of SE alleles (SE-/ SE-) in RA group was negatively associated with RA development (OR=0,28, 95% Cl 0,20, 5). In RA pts homozygote *0401/*0401 genotype was significantly more frequent among SE+/SE+ genotypes than in control group (17,8% and 1,5% respectively, OR=14,5, 95% Cl 3,1-93,4, p<0,0001). In RA group ACCP diagnostic level was revealed in 60,0% of cases, IgM RF — in 71,6% of cases. Most close relationship existed between ACCP and RF (r =0,66, p<0,05), less prominent — between SE and ACCP (r s=0,34, p<0,05). Correlation relationship between SE and RF was not revealed. In presence of at least one SE allele RF concentration was 280,4±414,3 lU/ml, in absence — 83,1 + 176,1 lU/ml (p<0,01). ACCP level in SE presence and absence was 56,2±44,6 lU/ml and 27,5±41,2 IU/ml respectively (p<0,01). Conclusion. HLA-DRB 1 (SE+) allele, ACCP and RF are significant markers of early RA development risk but ACCP and RF have diagnostic significance.

shared epitope (SE), rheumatoid arthritis, HLA-DRB 1 allele, shared epitope (SE), anti-cyclic citrullinated peptide antibodies (ACCP), rheumatoid factor (RF)

1. <div><p>Каратеев Д.Е. , Лучихина Е.Л. , Тюрина Л.Н. и др. Возможности ранней диагностики ревматоидного артрита в клинической практике на современном этапе (результаты наблюдений за московской когортой больных ранним артритом в рамках программы РАДИКАЛ). Тер. архив, 2008, 5, 8-13.</p><p>Ревматология. Клинические рекомендации. Под ред. Е.Л. Насонова. М, ГЭСУГАР-Медиа, 2006, 25-71.</p><p>Насонов Е. Л. Ревматоидный артрит как общемедицинская проблема. Тер. архив, 2004, 5, 5- 7.</p><p>Насонов Е. Л. Фармакотерапия ревматоидного артрита - взгляд в 21 век. Клин, мед., 2005, 6, 8-12.</p><p>Arnett F.C., Edworthy S.М., Bloch D.A. el al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr. Rheum., 1988, 31, 315-324.</p><p>Harrison B.J., Symmons D.P., Barrett E.M. et al. The performance of the 1987 ARA classification criteria for the rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. J.Rheumatol., 1998, 26, 2324-2330.</p><p>Huizinga T.W., Mash hold A'., Breedveld F. et al. Criteria for early rheumatoid arthritis. From Bayes’ low revised to new thoughts. Arthr.Rheum., 2002, 5, /155-1159.</p><p>Emery P., Breedveld F.C., Dougados M. et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann. Rheum. Dis., 2002, 61, 290-297.</p><p>Aletalia D., Breedveld F.C., Smolen J.S. The need for new classification criteria for rheumatoid arthritis. Arthr. Rheum., 2005, 52, 3333- 3336.</p><p>Lindqvist E., Eberhardt K., Bendtzen K. etal. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann. Rheum. Dis., 2005, 64, 196-201.</p><p>Bukhari М., Lunt М., Harrison B.J. etal. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthr. Rheum., 2002, 46, 906-912.</p><p>Mimori T Clinical significance of anti-ССР antibodies in rheumatoid arthritis. Inter.Med., 2005, И, 11221126.</p><p>Avouac J., Gossec L., Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated proteinantibodies in rheumatoid arthritis: a systematic litera­ture review. Ann. Rheum. Dis., 2006, 65, 845-851.</p><p>Niewold T.B., Harrison M.J., Paget S.A. Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. OJ.М., 2007, 100, 193-201.</p><p>Quinn M.A., Gough A.K., Green M.J. et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology, 2006. 45, 478-480.</p><p>Aho A'. Helliovaara М., Maatela J. et al. Rheumatoid factor amending clinical rheumatoid arthritis. J. Rheumatol., 1991, 18, 1282-1824.</p><p>Rantapaa-Dalilqvist S., de Jong B.A., Berglin E. et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthr. Rheum., 2003, 48. 2741-2749.</p><p>Nielen M.M., van Schaardenburg D., Reesink H. W. et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthr. Rheum., 2004, 50, 380-386.</p><p>Van der Helm-van Mil A.H. М., Verpoort K.N., le Cessie S. et al. The HLA—DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthr. Rheum., 2007, 56, 425-432.</p><p>Padyukov L., Silva C., Stolt P. et al. A gene-environ- ment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthr. Rheum., 2004, 50, 30853092.</p><p>KallbergH., Padyukov L., Plenge R.M. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am. J. Hum. Genet., 2007, 80, 867- 875.</p><p>Gregersen P.K., Silver J., Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthr. Rheum., 1987,30, 1205—1213.</p><p>Ronningen K.A., Spurkland A., Egeland T. et al. Rheumatoid arthritis may be primarily associated with HLA-DR4 molecules sharing a particular sequence at residues 67-74. Tissue Antigens, 1990,36, 235-240.</p><p>HLA in health and disease. Ed. R. Lechler, A. Warrens, Academic Press, 2000.</p><p>Berglin E., Padyukov L., Sundin U. et at. A combination of autoantibodies to cyclic citrullinated peptide (ССР) and HLA-DRBl locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthr. Res. Then, 2004, 6, 303-308.</p><p>van Gaalen F.A., van Aken J., Huizinga T.W. et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthr.Rheum., 2004, 50, 2113-2121.</p><p>Гусева И.А., Насонов Е.Л. Современные иммуноге- нетические и иммунологические аспекты ревматоидного артрита. Вестн. РАМН, 2008, 6, 7-13.</p><p>Александрова Е.Н., Чемерис Н.А., Каратеев Д.Е. и др. Антитела к циклическому цитруллинирован- ному пептиду при ревматоидном артрите. Тер. архив 2004, 12, 64-68.</p><p>Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 12-30.</p><p>Таукумова JI.A., Гусева И.А. Аллели HLA-DRBl у пациентов с ревматоидным артритом. Научно- практич. ревматол., 2004, 4, 29-34.</p><p>van Vemvoij W.J., ZedmanA.J. W. Anti-CCP2antibodies: an oven’iew and perspective of the diagnostic abilities of the serological marker for rheumatoid arthritis. Clin. Rev. Allerg. Immunol., 2008. 34, 36-39.</p><p>Huizinga T.W.J., Amos C.I., van der Helm-van Mil A.H.M. et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRBl shared epitope for antibodies to citrullinated proteins. Arthr. Rheum., 2005, 52, 3433-3438.</p><p>Nishimura K., Sugiyama D., Kogata Y. et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann. Intern. Med., 2007, 146, 797-808.</p><p>Van der Cruyssen B., Hoffman I.E., Peene I. et al. Prediction models for rheumatoid arthritis during diagnostic investigation: evaluation of combinations of rheumatoid factor, anti-citrullinated protein/peptide antibodies and the human leucocyte antigen-shared epitope. Ann. Rheum. Dis., 2007, 66, 364-369.</p><p>Ligeiro D., Fonseca J.E., Abade O.et al. Influence of human leucocyte antigen-DRBI on the susceptibility to rheumatoid arthritis and on the production of anti- cyclic citrullinated peptide antibodies in a Portuguese population. Ann. Rheum.Dis., 2007, 66, 246-248.</p><p>We у and С. М., Goronzy J. J. Association of MHC and rheumatoid arthritis: HLA polymorphisms in phenotypic variants of rheumatoid arthritis. Arthr. Res., 2000, 2, 212-216.</p><p>Gorman J.D, Lum R.F, Chen J.J. el al. Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3 240 rheumatoid ailhritis patients. Arthr. Rheum., 2004, 50, 400—412.</p><p>Mattey D.L., Thomson W., Oilier W. E. et a I. Association of DRBI shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years offol- lowup from the early rheumatoid ailhritis study. Arthr. Rheum., 2007, 56, 1408-1416.</p><p>Gonzalez-Gay M.A., Gonzalez-Juanatey C., Lopez- Diaz MJ. et al. HLA-DRBl and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthr. Rheum., 2007, 57, 125-133.</p><p>van der Helm-van Mil A. H., Verpoort K.N., Breedveld F. C. et al. The HLA-DRBl shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthr. Rheum., 2006, 54, 1117-1121.</p><p>Irigoyen P., Lee A. Т., Wener M.H. et at. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis (Contrasting effects of HLA-DR3 and the shared epitope alleles). Arthr. Rheum., 2005, 52, 3813-3818.</p><p>van der Helm-van Mil A.H.M., Huizinga T.W., Schreuder G.M.Th. An independent role of protective HLA class II alleles in rheumatoid arthritis severity and susceptibility. Arthr. Rheum., 2005, 52, 26372644.</p><p>Verpoor K.N., van Gaalen F.A., van der Helm-van Mil A. H. M. et al. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthr. Rheum., 2005, 52, 3058-3062.</p><p>Syversen S. W., Gaarder P. I., Goll G.L. et al. High anti- cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann. Rheum. Dis., 2008, 67, 212-217.</p><p>de Vries N., Tijssen H., van Riel P. L., van de Putte LB. Reshaping the shared epitope hypothesis: HLA- associated risk for rheumatoid arthritis is encoded by amino acid substitutions at positions 67—74 of the HLA-DRBl molecule. Arthr. Rheum., 2002, 46, 921-928.</p><p>du Montcel S. Т., Michou L., Petit-Teixeira E. Et.al., New classification of HLA-DRBl alleles supports the shared epitope hypothesis of rheumatoid arthritis susceptibility. Arthr. Rheum., 2005, 52, 1063-1068.</p><p>Michou L., Croiseau P., Petit-Teixeira E. et al. Validation of the reshaped shared epitope HLA-DRBl classification in rheumatoid arthritis. Arthr. Res. Ther., 2006, 8, 109-115.</p><p>Gourraud P.-A., Dieude P., Boyer J.F. et at. A new classification of HLA-DRBl alleles differentiates predisposing and protective alleles for autoantibody production in rheumatoid arthritis. Arthr. Res. Ther., 2007, 9. R27.</p><p>Karlson E. W., Chibnik L.B., Cui J. et al. Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study. Ann.Rheum. Dis., 2008, 67, 358-363.</p><p>Linn-Rasker S. P., Van der Helm-van Mil A.H., van Gaalen F.A. et al. Smoking is a risk factors for anti- CCP antibodies only in RA patiens that carry HLAtibodies in familial and sporadic rheumatoid arthritis. Ann. Rheum. Dis., 2008, 67, 466-470.</p><p>Kastbom A., Strandberg G., Lindroos A., Skogh T. Anti-ССР antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann. Rheum. Dis., 2004, 63, 10851089.</p><p>Meyer O., Nicaise-Roland P., Santos M.D. etal. Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis. Arthr. Res. Ther., 2006, 8, 40-48.</p><p>AlessandriC., BombardieriМ., Papa N. etal. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF-alpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann. Rheum.Dis., 2004, 63, 218-1221.</p></div><br />